Search research articles
Contact Us
Filters
Showing results (221-230 of 256) with videos related to
Page
of 26
Sort By:
International Clinical Psychopharmacology
|
August 8, 2023
Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia
Jung-Joon Moon, Ho-Sook Kim, Joo-Cheol Shim, et al.
Cancer Chemotherapy and Pharmacology
|
April 19, 2013
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer
Kyu-pyo Kim, Ho-Sook Kim, Sun Jin Sym, et al.
Science Advances
|
May 28, 2025
Deciphering linezolid-induced hematologic toxicity: Targeting TOP2A and TOP2B via its primary metabolite PNU142586
Vo Thuy Anh Thu, Nguyen Quynh Nhu, Nguyen Thi Van Anh, et al.
Infection & Chemotherapy
|
September 24, 2016
Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections
Yong Kyun Kim, Jin Ah Jung, Hyang Ki Choi, et al.
Drug Metabolism and Pharmacokinetics
|
January 5, 2010
Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene
Emiko Sugiyama, Su-Jun Lee, Sang Seop Lee, et al.
Biochemical and Biophysical Research Communications
|
December 8, 2009
Murrayafoline A attenuates the Wnt/beta-catenin pathway by promoting the degradation of intracellular beta-catenin proteins
Hyuk Choi, Jungsug Gwak, Munju Cho, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
March 14, 2023
Comprehensive lipid profiles investigation reveals host metabolic and immune alterations during anti-tuberculosis treatment: Implications for therapeutic monitoring
Nguyen Ky Anh, Nguyen Ky Phat, Nguyen Thi Hai Yen, et al.
Journal of Clinical Pharmacology
|
June 22, 2021
Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis
Yong-Soon Cho, Tae Won Jang, Hyo-Jung Kim, et al.
Oncology
|
May 5, 2012
A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity
Yoon Hee Choi, Tae Won Kim, Kyu-Pyo Kim, et al.
Archives of Pharmacal Research
|
December 15, 2005
In vitro metabolism of a new cardioprotective agent, KR-33028 in the human liver microsomes and cryopreserved human hepatocytes
Hyojin Kim, Yune-Jung Yoon, Hyunmi Kim, et al.
Page
of 26
Search research articles
Search
Showing results (221-230 of 256) with videos related to
Sort By:
Page
of 26
International Clinical Psychopharmacology
|
August 8, 2023
Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia
Jung-Joon Moon, Ho-Sook Kim, Joo-Cheol Shim, et al.
Cancer Chemotherapy and Pharmacology
|
April 19, 2013
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer
Kyu-pyo Kim, Ho-Sook Kim, Sun Jin Sym, et al.
Science Advances
|
May 28, 2025
Deciphering linezolid-induced hematologic toxicity: Targeting TOP2A and TOP2B via its primary metabolite PNU142586
Vo Thuy Anh Thu, Nguyen Quynh Nhu, Nguyen Thi Van Anh, et al.
Infection & Chemotherapy
|
September 24, 2016
Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections
Yong Kyun Kim, Jin Ah Jung, Hyang Ki Choi, et al.
Drug Metabolism and Pharmacokinetics
|
January 5, 2010
Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene
Emiko Sugiyama, Su-Jun Lee, Sang Seop Lee, et al.
Biochemical and Biophysical Research Communications
|
December 8, 2009
Murrayafoline A attenuates the Wnt/beta-catenin pathway by promoting the degradation of intracellular beta-catenin proteins
Hyuk Choi, Jungsug Gwak, Munju Cho, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
March 14, 2023
Comprehensive lipid profiles investigation reveals host metabolic and immune alterations during anti-tuberculosis treatment: Implications for therapeutic monitoring
Nguyen Ky Anh, Nguyen Ky Phat, Nguyen Thi Hai Yen, et al.
Journal of Clinical Pharmacology
|
June 22, 2021
Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis
Yong-Soon Cho, Tae Won Jang, Hyo-Jung Kim, et al.
Oncology
|
May 5, 2012
A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity
Yoon Hee Choi, Tae Won Kim, Kyu-Pyo Kim, et al.
Archives of Pharmacal Research
|
December 15, 2005
In vitro metabolism of a new cardioprotective agent, KR-33028 in the human liver microsomes and cryopreserved human hepatocytes
Hyojin Kim, Yune-Jung Yoon, Hyunmi Kim, et al.
Page
of 26